Immatics unveils promising, early-stage data for a top contender in the race to develop TCRs. Now it has to live up to expectations
Immatics has scored a significant advance in its quest to develop cell therapies for solid tumors.
Tuesday morning the biotech — based in Germany with a big operation in Houston — took the wraps off a set of promising preliminary data from an early-stage study of its TCR therapy, IMA203.
Examining the drug’s effect on 16 cancer patients who had already endured a median of 4 previous systemic treatments, researchers concluded that half — 8 — of them had registered an objective response against a range of solid tumor types. Three of the patients who didn’t respond were on the very lowest dose, the least likely to respond, while investigators tracked encouraging dose responses at higher levels.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 124,400+ biopharma pros reading Endpoints daily — and it's free.